MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4161/mabs.25282

Медицинская библиотека · mAbs · 2013

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Rafiq Sarwish, Siadak Anthony, Butchar Jonathan P, Cheney Carolyn, Lozanski Gerard, Jacob Naduparambil K, Lapalombella Rosa, McGourty Jackie, Moledor Meghan, Lowe Richard, Setter Ben, Jones Jeffrey, Flynn Joseph M, Andritsos Leslie, Devine Steven, Mo Xiaokui, Jarjoura David, Tridandapani Susheela, Algate Paul, Byrd John C, Muthusamy Natarajan

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

TRU-016 is a SMIP(TM) (monospecific protein therapeutic) molecule against the tetraspanin transmembrane family protein CD37 that is currently in Phase 2 trials in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). In an attempt to enhance the ADCC function of SMIP-016, the chimeric version of TRU-016, SMIP-016(GV) was engineered with a modification in a glycosylation site in the Fc domain. The wild-type and glycovariant SMIP proteins mediate comparable Type I antibody-like direct cytotoxicity in the presence of anti-human Fc crosslinker and show a similar tyrosine phosphorylation pattern post-treatment. However, NK cells stimulated with the SMIP-016(GV) exhibit enhanced activation and release 3-fold more interferon-γ compared with SMIP-016. SMIP-016(GV) shows enhanced ADCC function against cells expressing CD37 with NK cell effectors derived from both normal and CLL-affected individuals. Enhanced ADCC is observed against CLL cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) µg/mL on cells expressing minimal CD37 antigen. In support of the biological relevance of this, SMIP-016(GV) mediates effective ADCC against primary acute lymphoblastic leukemia (ALL) cells with low surface expression of CD37. Collectively, these data suggest potential use of the novel therapeutic agent SMIP-016(GV) with enhanced effector function for B cell malignancies, including CLL and ALL therapy.

Для цитирования: Rafiq Sarwish, Siadak Anthony, Butchar Jonathan P, Cheney Carolyn, Lozanski Gerard, Jacob Naduparambil K, Lapalombella Rosa, McGourty Jackie, Moledor Meghan, Lowe Richard, Setter Ben, Jones Jeffrey, Flynn Joseph M, Andritsos Leslie, Devine Steven, Mo Xiaokui, Jarjoura David, Tridandapani Susheela, Algate Paul, Byrd John C, Muthusamy Natarajan. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.. mAbs. 2013. DOI: 10.4161/mabs.25282.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.